NEWS
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer
Jaguar Health (NASDAQ:JAGX) has reported statistically significant improvement in breast cancer patients in its Phase 3 OnTarget trial for crofelemer, a cancer supportive care drug. The trial evaluated crofelemer for prophylaxis of cancer therapy-related diarrhea. Breast cancer patients accounted for nearly 180 of the 287 participants in this prophylactic clinical trial.
While the initial top line results did not meet the primary estimand for all tumor types, the subgroup analysis in adult breast cancer patients showed clinically meaningful improvement. This suggests crofelemer's potential to help breast cancer patients better adhere to their cancer therapies. The results have been submitted to a relevant oncology conference, and a full study report is expected to be submitted to a peer-reviewed journal.
Additionally, crofelemer has shown benefit in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with results to be presented at the upcoming American College of Gastroenterology Annual Scientific Meeting.
While the initial top line results did not meet the primary estimand for all tumor types, the subgroup analysis in adult breast cancer patients showed clinically meaningful improvement. This suggests crofelemer's potential to help breast cancer patients better adhere to their cancer therapies. The results have been submitted to a relevant oncology conference, and a full study report is expected to be submitted to a peer-reviewed journal.
Additionally, crofelemer has shown benefit in patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with results to be presented at the upcoming American College of Gastroenterology Annual Scientific Meeting.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1658Followers
91Following
13KVisitors
Follow
Rockhoundj : Gotta retest 1.40 and break